GLP1R and type 2 diabetes mellitus: Conversely, the risks which current T2D therapeutic interventions such as GLP-1 RAs pose on exacerbating these musculoskeletal comorbidities highlight the necessity of novel T2D therapeutics to mitigate and/or prevent these events.